1. Home
  2. AFYA vs NTLA Comparison

AFYA vs NTLA Comparison

Compare AFYA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFYA
  • NTLA
  • Stock Information
  • Founded
  • AFYA 1999
  • NTLA 2014
  • Country
  • AFYA Brazil
  • NTLA United States
  • Employees
  • AFYA N/A
  • NTLA N/A
  • Industry
  • AFYA Other Consumer Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • AFYA Real Estate
  • NTLA Health Care
  • Exchange
  • AFYA Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • AFYA 1.4B
  • NTLA 1.2B
  • IPO Year
  • AFYA 2019
  • NTLA 2016
  • Fundamental
  • Price
  • AFYA $14.70
  • NTLA $25.43
  • Analyst Decision
  • AFYA Hold
  • NTLA Buy
  • Analyst Count
  • AFYA 5
  • NTLA 19
  • Target Price
  • AFYA $18.10
  • NTLA $28.84
  • AVG Volume (30 Days)
  • AFYA 108.7K
  • NTLA 6.2M
  • Earning Date
  • AFYA 11-12-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • AFYA 1.58%
  • NTLA N/A
  • EPS Growth
  • AFYA 20.40
  • NTLA N/A
  • EPS
  • AFYA 1.36
  • NTLA N/A
  • Revenue
  • AFYA $650,778,153.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • AFYA $14.67
  • NTLA $9.20
  • Revenue Next Year
  • AFYA $8.34
  • NTLA N/A
  • P/E Ratio
  • AFYA $10.82
  • NTLA N/A
  • Revenue Growth
  • AFYA 15.60
  • NTLA 14.99
  • 52 Week Low
  • AFYA $13.47
  • NTLA $5.90
  • 52 Week High
  • AFYA $19.90
  • NTLA $28.25
  • Technical
  • Relative Strength Index (RSI)
  • AFYA 42.49
  • NTLA 62.70
  • Support Level
  • AFYA $14.61
  • NTLA $24.14
  • Resistance Level
  • AFYA $15.16
  • NTLA $28.24
  • Average True Range (ATR)
  • AFYA 0.43
  • NTLA 2.30
  • MACD
  • AFYA 0.01
  • NTLA -0.15
  • Stochastic Oscillator
  • AFYA 43.94
  • NTLA 66.79

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: